Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Axelsson

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
European Journal of Neurology|July 24, 2023
Paraneoplastic or not? Sirtuin 2 in anti-N-methyl-d-aspartate receptor encephalitisOskar Stevens-Jones, Hana Mojzisova, Martin Elisak, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2025
Plateau of practice effects and noise with repeat SDMT testing in multiple sclerosisLenka Novakova, Igal Rosenstein, Markus Axelsson, et al.
Multiple Sclerosis and Related Disorders|May 8, 2021
Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of lifeClara Constantinescu, Lenka Novakova, Anne Frandsen Brandt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 20, 2022
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumabMagnus Johnsson, Helen H Farman, Kaj Blennow, et al.
Journal of the Neurological Sciences|September 7, 2015
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosisLenka Novakova, Markus Axelsson, Clas Malmeström, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2016
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantroneAnnika Öhrfelt, Markus Axelsson, Clas Malmeström, et al.
Multiple Sclerosis and Related Disorders|September 18, 2024
The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center studySofia Sandgren, Lenka Novakova, Anna Nordin, et al.
Addiction Biology|June 2, 2025
Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin-ATim Lyckenvik, Malin Woock, Kalle Johansson, et al.
Brain and Behavior|March 7, 2024
Medically unexplained symptoms are common in women in tertiary neurological healthcare center: A survey cohort study of persons investigated for suspected multiple sclerosisLenka Novakova, Anna Karin Hedström, Markus Axelsson, et al.
Frontiers in Immunology|March 25, 2017
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple SclerosisAvadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
European Journal of Neurology|July 24, 2023
Paraneoplastic or not? Sirtuin 2 in anti-N-methyl-d-aspartate receptor encephalitisOskar Stevens-Jones, Hana Mojzisova, Martin Elisak, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2025
Plateau of practice effects and noise with repeat SDMT testing in multiple sclerosisLenka Novakova, Igal Rosenstein, Markus Axelsson, et al.
Multiple Sclerosis and Related Disorders|May 8, 2021
Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of lifeClara Constantinescu, Lenka Novakova, Anne Frandsen Brandt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 20, 2022
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumabMagnus Johnsson, Helen H Farman, Kaj Blennow, et al.
Journal of the Neurological Sciences|September 7, 2015
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosisLenka Novakova, Markus Axelsson, Clas Malmeström, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2016
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantroneAnnika Öhrfelt, Markus Axelsson, Clas Malmeström, et al.
Multiple Sclerosis and Related Disorders|September 18, 2024
The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center studySofia Sandgren, Lenka Novakova, Anna Nordin, et al.
Addiction Biology|June 2, 2025
Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin-ATim Lyckenvik, Malin Woock, Kalle Johansson, et al.
Brain and Behavior|March 7, 2024
Medically unexplained symptoms are common in women in tertiary neurological healthcare center: A survey cohort study of persons investigated for suspected multiple sclerosisLenka Novakova, Anna Karin Hedström, Markus Axelsson, et al.
Frontiers in Immunology|March 25, 2017
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple SclerosisAvadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, et al.
Pageof 9